Navigation Links
MedQuist Announces Additions to Board of Directors
Date:9/4/2008

MOUNT LAUREL, N.J., Sept. 4 /PRNewswire-FirstCall/ -- MedQuist Inc. (Nasdaq: MEDQ) today announced that its board of directors has elected John F. Jastrem, Colin J. O'Brien, and Andrew Vogel to join the board, effective September 4, 2008. Prior to the election of the new directors, the board of directors expanded the size of the board from seven to 10 members.

According to MedQuist Chairman of the Board Robert Aquilina, "We are pleased to have this opportunity to further enhance the quality and experience on the board. John, Colin and Andrew were identified as well-qualified and independent director candidates with a wide breadth of work experience. We welcome these new members and their input, and we believe they will be a tremendous asset to our board."

John F. Jastrem, 53, has been president and CEO of Exhibitgroup/Giltspur ("EG"), a division of Viad Corp. (NYSE: VVI), since 2006. EG is an industry leader in experience marketing, specializing in exhibit design, production and program management. Previously, he was an executive for eight years with Omnicom Group Inc., the world's largest advertising and marketing services company. He started with Omnicom in 1998 as chairman and CEO of Rapp Collins Worldwide-Dallas ("RCW"), the global leader in direct response marketing and database management. Prior to his tenure at Omnicom, he was president and CEO of TEAM Consultants, which specialized in strategic planning, financing, interim management, technology-enabled solutions, and mergers and acquisitions. Previously, he served as a member of the executive team at Knapp Communications Corporation (the publisher of Architectural Digest and Bon Appetit magazines), and at Wickes Companies Inc., an international retailer and manufacturer. He started his career with Andersen LLP, where he earned his CPA.

Colin J. O'Brien, 69, has been retired since 2001. He was employed in various positions with Xerox Corporation from 1992-2001, including vice president of Business Development and Systems Strategy, CEO of Xerox's New Enterprise Board, and executive chairman of XESystems Inc., a subsidiary of Xerox. In 1986, Mr. O'Brien formed an investment company with E.M. Warburg Pincus & Co. Inc., making a number of acquisitions in defense electronics. Prior to that time, he served as chairman and chief executive of Times Fiber Communications Inc., a publicly traded company, and president of General Instrument's cable television operations. He has held management positions with Union Carbide in both Canada and Europe, and has served on a number of public and private boards.

Andrew Vogel, 35, is a Managing Member of ZM Capital, a media-focused private equity firm, and has been working at ZelnickMedia Corp. since late 2003. He is an accomplished private equity investor with experience in several industries and geographic markets. Prior to joining ZelnickMedia, he was an investment professional at Ripplewood Holdings ("Ripplewood"), a private equity firm with several billion dollars of capital under management. Previously, he was an associate at McCown De Leeuw & Co., a private equity firm specializing in leveraged build-ups, and an investment banker in Lehman Brothers' Mergers and Acquisitions group. Mr. Vogel is a director of ThinkMap Inc.

About MedQuist:

MedQuist is the largest Medical Transcription Service Organization (MTSO) in the world, and a leader in technology-enabled clinical documentation workflow. MedQuist's enterprise solutions -- including mobile voice capture devices, speech recognition, Web-based workflow platforms, and global network of medical editors -- help healthcare facilities improve patient care, increase physician satisfaction, and lower operational costs. For more information, please visit http://www.medquist.com.

"Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995: Statements in this press release regarding MedQuist's business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. Actual outcomes and results may differ materially from what is expressed or forecasted in forward-looking statements. As a result, forward-looking statements speak only as of the date they were made, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE MedQuist Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MedQuist and StructuRad Form Partnership to Integrate Report Macros into SpeechQ for Radiology(TM)
2. MedQuist Reports First Quarter 2008 Results
3. Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology
4. Martek Announces Third Quarter 2008 Financial Results
5. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
6. China Bio Energy Holdings Group Announces Participation in the Susquehanna Second Annual Beijing Management Summit
7. American Oriental Bioengineering Announces Participation in September Investor Conferences
8. Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira
9. Mindray Medical International Announces Second Quarter 2008 Results
10. BioMS Medical announces its intention to renew a normal course issuer bid
11. Exosome Diagnostics Announces Additions to Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
Breaking Biology News(10 mins):